Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  The American journal of geriatric psychiatry

• Publication date

  2017-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jagp.2017.06.007PMID 28739263
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Placebo‐controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression

  2016cited by this paper
• A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.

  2016cited by this paper
• Neuromodulation Therapies for Geriatric Depression

  2015cited by this paper
• Safety and efficacy of ketamine infusion in late onset depression, and conversion to treatment response

  2015cited by this paper
• Leptin/LepRb in the Ventral Tegmental Area Mediates Anxiety-Related Behaviors

  2015cited by this paper
• Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis

  2015cited by this paper
• Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.

  2015cited by this paper
• The use of ketamine as an antidepressant: a systematic review and meta‐analysis

  2015cited by this paper
• Ketamine administration in depressive disorders: a systematic review and meta-analysis

  2014cited by this paper
• Pilot dose–response trial of i.v. ketamine in treatment-resistant depression

  2014cited by this paper
• Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: a case report.

  2014cited by this paper
• Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder.

  2014cited by this paper
• Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

  2013cited by this paper
• Ketamine as a new treatment for depression: A review of its efficacy and adverse effects

  2013cited by this paper
• Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

  2013cited by this paper
• Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.

  2011cited by this paper
• Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression.

  2011cited by this paper
• RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ)

  2010cited by this paper
• Depression in older adults.

  2009cited by this paper
• Depression, chronic diseases, and decrements in health: results from the World Health Surveys.

  2007cited by this paper
• Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome.

  2005cited by this paper
• Meta-analysis of the brief psychiatric rating scale factor structure.

  2005cited by this paper
• Long-term outcome of patients who receive ketamine during research.

  2001cited by this paper
• Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS)

  1998cited by this paper
• Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions.

  1998cited by this paper
• SAFTEE: data system for side effect assessment scale.

  1986cited by this paper
• SAFTEE: data system for side effect assessment scale.

  1986cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• A Rating Scale for Mania: Reliability, Validity and Sensitivity

  1978cited by this paper
• CUMULATIVE ILLNESS RATING SCALE

  1968cited by this paper

• The spectrum of bipolar disorder in older adults.

  2026cites this paper
• Systematic review of clinical effectiveness of interventions for treatment resistant late-life depression.

  2025influential citation
• Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies

  2025cites this paper
• Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment.

  2025cites this paper
• Treatment-resistant late-life depression prevalence and clinical/sociodemographic correlates: An electronic health records study.

  2025cites this paper
• Role of ketamine in treatment-resistant depression

  2025cites this paper
• Ketamine treatment for depression in elderly inpatients: an observational case series

  2025cites this paper
• Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians.

  2025cites this paper
• Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program

  2025cites this paper
• Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the use of ketamine in psychiatric practice

  2025cites this paper
• Expanding Ketamine Application for Treatment of Acute Suicidality in Long-Duration Spaceflight.

  2025cites this paper
• Can ketamine therapy overcome treatment-resistant depression in Alzheimer's disease and older adults? Preclinical and clinical evidence.

  2025cites this paper
• Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review

  2025influential citation
• Ketamine and Esketamine for Late-Life Depression: A Systematic Review of Efficacy, Safety, and Tolerability.

  2025cites this paper
• Effects of ketamine and esketamine on death, suicidal behaviour, and suicidal ideation in psychiatric disorders: A systematic review and meta-analysis

  2025cites this paper
• Inflammatory response to repeated subcutaneous esketamine in treatment-resistant depression: The role of baseline C-reactive protein.

  2025cites this paper
• The evidence for ketamine treatment in older adults with psychiatric illness: a scoping review

  2025influential citation
• Rapid and long-lasting effects of subcutaneous esketamine on suicidality: An open-label study in patients with treatment-resistant depression.

  2024cites this paper
• Repeated subcutaneous esketamine on treatment-resistant depression: An open-label dose titration study.

  2024cites this paper
• Comparison of the Antianhedonic Effects of Repeated-dose Intravenous Ketamine in Older and Younger Adults with Major Depressive Episode

  2024cites this paper
• Is lack of goal-conflict-specific rhythmicity a biomarker for treatment resistance in generalised anxiety but not social anxiety or major depression?

  2024cites this paper
• Fast-acting antidepressant-like effects of ketamine in aged male rats

  2024cites this paper
• The effectiveness of ketamine in medication of treatment-resistant depression - review

  2024cites this paper
• Dépression résistante aux traitements chez les personnes âgées

  2024cites this paper
• Subcutaneous ketamine reduces suicide risk and improves functioning in depression: A proof-of-concept study.

  2024cites this paper
• Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R).

  2024cites this paper
• Personalized use of ketamine and esketamine for treatment-resistant depression

  2024cites this paper
• Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial

  2023cites this paper
• Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)—Phase II single-arm open-label feasibility study

  2023cites this paper
• A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders.

  2023cites this paper
• Mechanism of Antidepressant Action of (2R,6R)-6-Hydroxynorketamine (HNK) and Its Compounds: Insights from Proteomic Analysis

  2023cites this paper
• REPEATED DOSES OF SUBCUTANEOUS ESKETAMINE IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION: CASE SERIES IN A GENERAL HOSPITAL IN SOUTHERN BRAZIL

  2023cites this paper
• Ketamine study: Protocol for naturalistic prospective multicenter study on subcutaneous ketamine infusion in depressed patients with active suicidal ideation

  2023cites this paper
• A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult

  2023cites this paper
• The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders.

  2023cites this paper
• Ketamine for the treatment of major depression: a systematic review and meta-analysis

  2023cites this paper
• A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression.

  2023cites this paper
• Biological factors influencing depression in later life: role of aging processes and treatment implications

  2023cites this paper
• A New Solution to an Age-old Problem: A Review of Ketamine and Esketamine for Treatment-resistant Depression in Late Life

  2023cites this paper
• Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition.

  2022cites this paper
• Efecto de una sola infusión de ketamina sobre síntomas depresivos en pacientes geriátricos sometidos a cirugía oftalmológica: ensayo controlado aleatorizado**

  2022cites this paper
• Suizidpräventive Effekte von Ketamin und Esketamin

  2022cites this paper
• Cardiovascular side effects of non-SSRI antidepressants are of concern in high-risk patients

  2022cites this paper
• Clinical use of ketamine in psychiatric disorders

  2022cites this paper
• Hallucinogen Use and Misuse in Older Adults.

  2022cites this paper
• Ketamine for resistant depression: a scoping review

  2022influential citation
• Potential advantages of ketamine over electroconvulsive therapy in the treatment of nonrefractory severe depression in older patients with multiple medical comorbidities

  2022cites this paper
• SYSTEMATIC REVIEW AND META-ANALYSIS Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis

  2022cites this paper
• Prophylactic (R,S)-Ketamine Is Effective Against Stress-Induced Behaviors in Adolescent but Not Aged Mice

  2022cites this paper
• Effects of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, on Perceived Stress and Cognitive Function Among Patients With Late-Life Depression: A Randomized, Double-Blind, Sertraline- and Placebo-Controlled Trial

  2022cites this paper
• Ketamine for suicidality: An umbrella review

  2022cites this paper
• Acute (R,S)-Ketamine Administration Induces Sex-Specific Behavioral Effects in Adolescent but Not Aged Mice

  2022cites this paper
• Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression

  2022cites this paper
• Novel and emerging treatments for major depression.

  2022cites this paper
• A unique case of very low‐dose subcutaneous ketamine use: Maintenance option of ketamine for treatment‐resistant depression

  2022cites this paper
• The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review.

  2021cites this paper
• Depression and Anxiety Disorders

  2021cites this paper
• Treatment resistant depression

  2021cites this paper
• Overview of ketamine for major depression: efficacy and effectiveness

  2021cites this paper
• Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity

  2021cites this paper
• Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.

  2021cites this paper
• Ketamine for Depression in Older Adults.

  2021cites this paper
• Recent developments in geriatric psychopharmacology

  2021cites this paper
• Ketamine for depression

  2021cites this paper
• Cautious optimism and a call for additional studies

  2021cites this paper
• Meta-Analysis: Hemodynamic Responses to Sub-anesthetic Doses of Ketamine in Patients With Psychiatric Disorders

  2021cites this paper
• Single Subcutaneous Ketamine Dose Followed by Oral Ketamine for Depression Symptoms in Hospice Patients: A Case Series

  2021cites this paper
• Subcutaneous Ketamine in Depression: A Systematic Review

  2021cites this paper
• Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997–2019

  2021cites this paper
• Study protocol for SKIPMDD: subcutaneous ketamine infusion in palliative care patients with advanced life limiting illnesses for major depressive disorder (phase II pilot feasibility study)

  2021cites this paper
• Molecular Basis of Late-Life Depression

  2021cites this paper
• Ketamine treatment for depression: A model of care

  2021cites this paper
• Ketamine in depression and electroconvulsive therapy

  2021cites this paper
• Ketamine for Treatment of Mood Disorders and Suicidality: A Narrative Review of Recent Progress

  2021influential citation
• Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses

  2021cites this paper
• Identification of an Optimal Dose of Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Bayesian Adaptive Randomization Trial

  2021cites this paper
• Development of the Ketamine Side Effect Tool (KSET).

  2020cites this paper
• The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases

  2020cites this paper
• Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets

  2020cites this paper
• Virtual Reality and Psychedelics for the Treatment of Psychiatric Disease: A Systematic Literature Review

  2020cites this paper
• Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.

  2020cites this paper
• Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression

  2020cites this paper
• Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression

  2020influential citation
• Urothelial toxicity of esketamine in the treatment of depression

  2020cites this paper
• Safety of Repeated Administration of Parenteral Ketamine for Depression

  2020cites this paper
• Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression

  2020influential citation
• Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.

  2020cites this paper
• A systematic review of ketamine for the treatment of depression among older adults

  2020cites this paper
• Ketamine for depression clinical issues.

  2020cites this paper
• Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement.

  2020cites this paper
• Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression

  2019cites this paper
• Stress and Ketamine, Bimodal Influence on Cognitive Functions

  2019cites this paper
• Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.

  2019cites this paper
• Interaction of Sex and Age on the Dissociative Effects of Ketamine Action in Young Healthy Participants

  2019cites this paper
• Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions.

  2018cites this paper
• Treatment of Behavior Disturbances with Ketamine in a Patient Diagnosed with Major Neurocognitive Disorder.

  2018cites this paper
• Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting.

  2018cites this paper
• Challenges in management of Major Depression in patients with co-morbid medical conditions

  2018cites this paper
• Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression

  2018cites this paper
• Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine

  2018cites this paper